Inspire Medical Systems, Inc. Announces FDA Approval of New Sensing Lead

Download as PDF

MINNEAPOLIS, January 29, 2019 — Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a
medical technology company focused on the development and commercialization of innovative and
minimally invasive solutions for patients with obstructive sleep apnea, announced today that the U.S.
Food and Drug Administration (“FDA”) has approved for use in the U.S. Inspire’s new sensing lead.
Inspire intends to introduce the new sensing lead to its U.S. medical center customers in March 2019.

The sensing lead monitors a patient’s respiratory pattern as the implanted Inspire system delivers
stimulation to the upper airway in order to prevent obstructions during sleep. The new sensing lead has a
significantly smaller profile, including a reduction in diameter of 49 percent, as compared to the prior
design. This smaller profile is intended to improve the patient’s comfort. The new design also
incorporates several features to enable easier implanting and potentially reduce surgical time for an ENT
surgeon.

“We are pleased to receive FDA approval of the new sensing lead for Inspire therapy,” said Tim Herbert,
President and Chief Executive Officer of Inspire Medical Systems. “The improved features of the sensing
lead have led to more reliable and simpler implant procedures, as demonstrated by our recent European
experience with the new sensing lead since its introduction in Europe in October 2018. We believe that
the product enhancements with this next generation sensing lead will continue to have a positive impact
on the commercial opportunity for Inspire therapy.”

About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of
innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s
proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides
a safe and effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-
looking statements, including, without limitation, statements regarding the timing for Inspire’s
introduction of its new sensing lead, the potential for improved patient comfort and easier implanting with
this new sensing lead and a positive impact on the commercial opportunity for Inspire therapy. In some
cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’
‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ “future,” “outlook,” ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’
‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential,’’ ‘‘continue,’’ or the negative of these
terms or other similar expressions, although not all forward-looking statements contain these words.

These forward-looking statements are based on management’s current expectations and involve known
and unknown risks and uncertainties that may cause our actual results, performance or achievements to be
materially different from any future results, performance or achievements expressed or implied by the
forward-looking statements. Such risks and uncertainties include, among others: estimates regarding the
annual total addressable market for our Inspire therapy in the U.S. and our market opportunity outside the
U.S., future results of operations, financial position, research and development costs, capital requirements
and our needs for additional financing; commercial success and market acceptance of our Inspire therapy;
our ability to achieve and maintain adequate levels of coverage or reimbursement for our Inspire system
or any future products we may seek to commercialize; competitive companies and technologies in our
industry; our ability to expand our indications and develop and commercialize additional products and
enhancements to our Inspire system; our business model and strategic plans for our products, technologies
and business, including our implementation thereof; our ability to accurately forecast customer demand
for our Inspire system and manage our inventory; our ability to expand, manage and maintain our direct
sales and marketing organization, and to market and sell our Inspire system in markets outside of the
U.S.; our ability to increase the number of active medical centers implanting Inspire therapy; our ability to
hire and retain our senior management and other highly qualified personnel; our ability to commercialize
or obtain regulatory approvals for our Inspire therapy and system, or the effect of delays in
commercializing or obtaining regulatory approvals; FDA or other U.S. or foreign regulatory actions
affecting us or the healthcare industry generally, including healthcare reform measures in the U.S. and
international markets; and our ability to establish and maintain intellectual property protection for our
Inspire therapy and system or avoid claims of infringement. Other important factors that could cause
actual results, performance or achievements to differ materially from those contemplated in this press
release can be found under the captions “Risk Factors” and “Management’s Discussion and Analysis of
Financial Condition and Results of Operations” in our final prospectus filed under Rule 424(b) on
December 7, 2018, as such factors may be updated from time to time in our other filings with the SEC,
which are accessible on the SEC’s website at www.sec.gov. These and other important factors could
cause actual results to differ materially from those indicated by the forward-looking statements made in
this press release. Any such forward-looking statements represent management’s estimates as of the date
of this press release. While we may elect to update such forward-looking statements at some point in the
future, unless required by applicable law, we disclaim any obligation to do so, even if subsequent events
cause our views to change. Thus, one should not assume that our silence over time means that actual
events are bearing out as expressed or implied in such forward-looking statements. These forward-looking
statements should not be relied upon as representing our views as of any date subsequent to the date of
this press release.

Investor and Media Contact:
Bob Yedid
LifeSci Advisors
bob@lifesciadvisors.com
646-597-6989